（文章来源：证券日报） 证券日报网讯 1月8日，金河生物发布公告称，公司于2025年12月26日披露了《关于变更持续督导保荐 机构及保荐代表人的公告》。因公司聘请平安证券股份有限公司（简称"平安证券"）担任公司2025年度 以简易程序向特定对象发行股票的保荐机构，原保荐机构东方证券股份有限公司（简称"东方证券"）对 公司2021年度非公开发行股票并上市尚未完成的持续督导工作由平安证券承接。鉴于公司保荐机构已变 更，为规范募集资金管理和使用，保护中小投资者的权益，根据相关规定，近日，公司与中国民生银行 股份有限公司呼和浩特分行、平安证券共同签订《募集资金三方监管协议》；公司及控股子公司金河佑 本生物制品有限公司与招商银行股份有限公司呼和浩特分行、平安证券共同签订《募集资金四方监管协 议》。 ...

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]

Core Viewpoint - Jinhe Biology (002688.SZ) announced the approval of a new veterinary drug, an inactivated vaccine for porcine encephalitis (A6-C strain), developed in collaboration with its subsidiaries and Beijing Huikang Yisheng Technology Co., Ltd. [1] Group 1 - The new veterinary drug was approved by the Ministry of Agriculture and Rural Affairs after review [1] - The vaccine is developed by Jinhe Biology's subsidiaries: Hangzhou Youben Animal Vaccine Co., Ltd., Jinhe Youben Biological Products Co., Ltd., and Hohhot Youben Vaccine Technology Co., Ltd. [1] - The approval includes the issuance of a "New Veterinary Drug Registration Certificate" [1]

金河生物科技股份有限公司 关于子公司获得新兽药注册证书的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 根据国家《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查， 批准金河生物科技股份有限公司（以下简称"公司"）子公司杭州佑本动物疫苗 有限公司（以下简称"杭州佑本"）、子公司金河佑本生物制品有限公司（以下 简称"金河佑本"）、子公司呼和浩特佑本疫苗科技有限公司（以下简称"呼市 佑本"）与北京汇康益生科技有限公司联合开发的猪乙型脑炎灭活疫苗（A6-C 株）为新兽药，核发了《新兽药注册证书》。详情如下： 一、新兽药产品基本情况 新兽药名称：猪乙型脑炎灭活疫苗（A6-C 株） 证券代码：002688 证券简称：金河生物 公告编号：2026-002 类别：三类 新兽药注册证书号：（2026）新兽药证字 11 号 贮藏与有效期：2～8℃保存，有效期为 18 个月。 二、新兽药产品研发情况和相关市场背景情况 乙型脑炎是一种由病毒引起的人畜共患传染病，猪是其重要宿主和传染源。 目前我国猪场主要使用活疫苗（SA14-14-2 株）进行免疫，长期使用存 ...

证券代码：002688 证券简称：金河生物 公告编号：2026-001 金河生物科技股份有限公司 关于变更保荐机构后重新签订募集资金监管协议的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 26 日披 露了《关于变更持续督导保荐机构及保荐代表人的公告》。因公司聘请平安证券 股份有限公司（以下简称"平安证券"）担任公司 2025 年度以简易程序向特定 对象发行股票的保荐机构，原保荐机构东方证券股份有限公司（以下简称"东方 证券"）对公司 2021 年度非公开发行股票并上市尚未完成的持续督导工作由平 安证券承接。鉴于公司保荐机构已变更，为规范募集资金管理和使用，保护中小 投资者的权益，根据《上市公司募集资金监管规则》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等相关法律、法规和规范性文 件及公司《募集资金管理办法》的相关规定，近日，公司与中国民生银行股份有 限公司呼和浩特分行、平安证券共同签订《募集资金三方监管协议》；公司及控 股子公司金河佑本生 ...

Core Viewpoint - The animal health sector experienced a 0.99% increase on January 8, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4082.98, down 0.07%, and the Shenzhen Component Index closed at 13959.48, down 0.51% [1]. - The animal health sector stocks showed varied performance, with BioShares leading the gains at 3.10% [1]. Group 2: Stock Performance - Key stocks in the animal health sector included: - BioShares (600201) closed at 16.61 with a 3.10% increase and a trading volume of 517,400 shares, totaling 853 million yuan [1]. - Huisheng Biological (300871) closed at 22.46, up 2.23%, with a trading volume of 86,000 shares, totaling 193 million yuan [1]. - Dayu Biological (920970) closed at 8.02, up 2.17%, with a trading volume of 19,900 shares, totaling 15.81 million yuan [1]. - Other notable stocks included PlaiKe (603566) and Shunlian Biological (688098), with increases of 1.90% and 1.71% respectively [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 10.1262 million yuan from institutional investors, while retail investors contributed a net inflow of 37.4241 million yuan [2]. - Notably, the main funds showed a net outflow of 47.5503 million yuan from speculative funds [2]. Group 4: Detailed Capital Flow by Stock - BioShares (600201) had a net inflow of 40.3094 million yuan from main funds, while it experienced a net outflow of 8.4352 million yuan from speculative funds [3]. - Gold River Biological (002688) saw a net inflow of 13.2219 million yuan from main funds, with a net outflow of 3.8181 million yuan from speculative funds [3]. - ST Green Health (002868) had a net inflow of 9.7760 million yuan from main funds, but a significant net outflow of 20.7609 million yuan from speculative funds [3].

Group 1 - The company has successfully established a production capacity of 3,000 tons of astaxanthin per year [1] - The related product, red yeast rice as a feed additive, has received the necessary product approval number and is currently in the market promotion phase [1] - The company is expected to provide further details on the operational situation in future announcements [1]

Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

证券日报网讯 12月30日，金河生物（002688）发布公告称，公司拟为全资子公司金河环保向建设银行 呼和浩特分行申请的10，000万元固定资产贷款提供连带责任保证担保，用于污水处理厂扩容及水资源 再生利用提标扩建工程。截至公告披露日，公司及子公司累计对外担保余额为46，305.34万元，占公司 2024年经审计归属于母公司所有者净资产的20.61%，不存在逾期担保。 ...